| Literature DB >> 31549150 |
B O Ojikutu1,2,3, K H Mayer3,4,5.
Abstract
HIV preexposure prophylaxis (PrEP) with oral tenofovir/emtricitabine is an effective means of decreasing human immunodeficiency virus (HIV) acquisition among women. However, few women are prescribed and are taking PrEP. This article offers perspectives on barriers to use and strategies to increase uptake among women.Entities:
Keywords: HIV and women; PrEP; pre-exposure prophylaxis
Mesh:
Substances:
Year: 2020 PMID: 31549150 PMCID: PMC7529034 DOI: 10.1093/infdis/jiz416
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226